An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial led by National Institutes of Health scientists and their colleagues. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.
MERS and SARS News Releases
National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease.
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.